BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 36265135)

  • 1. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
    Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
    JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Wittmann I; Molnár GA; Nagy D; Müller V; Bogos K; Nagy P; Kenessey I; Wéber A; Polivka L; Pálosi M; Szlávik J; Rokszin G; Müller C; Szekanecz Z; Kásler M
    Front Immunol; 2022; 13():919408. PubMed ID: 35935993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
    Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
    BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study.
    Wright BJ; Tideman S; Diaz GA; French T; Parsons GT; Robicsek A
    Lancet Respir Med; 2022 Jun; 10(6):557-565. PubMed ID: 35227415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
    Wang W; Kaelber DC; Xu R; Berger NA
    JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
    Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
    J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
    Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
    Efe C; Taşçılar K; Gerussi A; Bolis F; Lammert C; Ebik B; Stättermayer AF; Cengiz M; Gökçe DT; Cristoferi L; Peralta M; Massoumi H; Montes P; Cerda E; Rigamonti C; Yapalı S; Adali G; Çalışkan AR; Balaban Y; Eren F; Eşkazan T; Barutçu S; Lytvyak E; Zazueta GM; Kayhan MA; Heurgue-Berlot A; De Martin E; Yavuz A; Bıyık M; Narro GC; Duman S; Hernandez N; Gatselis NK; Aguirre J; Idilman R; Silva M; Mendizabal M; Atay K; Güzelbulut F; Dhanasekaran R; Montano-Loza AJ; Dalekos GN; Ridruejo E; Invernizzi P; Wahlin S
    J Autoimmun; 2022 Oct; 132():102906. PubMed ID: 36088883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
    Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
    medRxiv; 2021 Oct; ():. PubMed ID: 34642696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients.
    Wand O; Nacasch N; Fadeela A; Shashar M; Grupper A; Benchetrit S; Erez D; Shitrit P; Cohen-Hagai K
    J Nephrol; 2022 Jun; 35(5):1479-1487. PubMed ID: 35175577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
    Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
    Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends and Correlates of Breakthrough Infections With SARS-CoV-2.
    Yamal JM; Appana S; Wang M; Leon-Novelo L; Bakota E; Ye Y; Sharma S; Morrison AC; Marko D; Linder SH; Rector A; Jetelina KK; Boerwinkle E; de Oliveira Otto M
    Front Public Health; 2022; 10():856532. PubMed ID: 35619825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
    Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
    Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
    Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative.
    Anzalone AJ; Sun J; Vinson AJ; Beasley WH; Hillegass WB; Murray K; Hendricks BM; Haendel M; Geary CR; Bailey KL; Hanson CK; Miele L; Horswell R; McMurry JA; Porterfield JZ; Vest MT; Bunnell HT; Harper JR; Price BS; Santangelo SL; Rosen CJ; McClay JC; Hodder SL;
    PLoS One; 2023; 18(1):e0279968. PubMed ID: 36603014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Darby B; Alexander V; Murphy J
    Vaccine; 2023 Feb; 41(7):1295-1298. PubMed ID: 36690560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.